Compare Marathon Petroleum Corp (MPC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Novo Nordisk A/S — how do they compare? Marathon Petroleum Corp trades at $460.5 (market cap $124.20B), while Novo Nordisk A/S trades at $38.07 (market cap $168.73B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Novo Nordisk A/S for 116 Days on average.
| MPC | NVO | |
|---|---|---|
Market Cap | $124.20B | $168.73B |
Volume | 1,923,373 | 13,531,267 |
Sector | Energy | Health |
52-Week High | $463.34 | $63.98 |
52-Week Low | $162.63 | $35.29 |
Typical Hold Time | 54 Days | 116 Days |
Enterprise Value | $150.72B | $183.05B |
Dividend Yield | 0.9% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $463.34, up 7.17% over 24 hours and near its 52-week high. The stock exhibits strong bullish momentum with consistent earnings beats and robust profitability metrics, including a 47.9% ROE. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export curbs pose a risk. Technical indicators show bullish moving averages but an overbought RSI, with key resistance at $452.
MPC presents a compelling investment case with solid fundamentals, high analyst buy ratings (75.76%), and a consensus price target of $420.30. Upside is driven by elevated refining margins and earnings growth, but risks include regulatory threats to exports and volatile energy markets. The stock's current premium to target suggests cautious optimism amid near-term overbought conditions.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
